Literature DB >> 10379589

Presumed intraventricular meningioma treated by embolisation and the gamma knife.

T Terada1, H Yokote, M Tsuura, Y Kinoshita, R Takehara, K Kubo, K Nakai, T Itakura.   

Abstract

A 58-year-old woman with a presumed incidentally discovered meningioma in the left lateral ventricle was treated by superselective embolisation and gamma knife therapy. The diameter of the tumour was 40 mm, and its main feeding artery was the left lateral posterior choroidal artery. This vessel was embolised with microcoils. At 8 months following embolisation, the diameter of the tumour had decreased and was stable. The gamma knife was chosen as an adjuvant therapy for the further control 13 months after embolisation. Embolisation and gamma knife therapy may be an alternative treatment for meningiomas where surgical resection appears difficult.

Entities:  

Mesh:

Year:  1999        PMID: 10379589     DOI: 10.1007/s002340050759

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  3 in total

Review 1.  Natural history of intraventricular meningiomas: systematic review.

Authors:  Benedito Jamilson Araújo Pereira; Antônio Nogueira de Almeida; Wellingson Silva Paiva; Paulo Henrique Pires de Aguiar; Manoel Jacobsen Teixeira; Suely Kazue Nagahashi Marie
Journal:  Neurosurg Rev       Date:  2018-08-15       Impact factor: 3.042

2.  Tumor Volume Decrease via Feeder Occlusion for Treating a Large, Firm Trigone Meningioma.

Authors:  Takuma Nakashima; Norikazu Hatano; Fumiaki Kanamori; Shinsuke Muraoka; Teppei Kawabata; Syuntaro Takasu; Tadashi Watanabe; Takao Kojima; Tetsuya Nagatani; Yukio Seki
Journal:  NMC Case Rep J       Date:  2017-12-06

3.  Preoperative obliteration of choroidal arteries in the treatment of large hypervascular tumors in the lateral ventricle.

Authors:  Yukihiro Yamao; Kazumichi Yoshida; Akira Ishii; Masahiro Tanji; Masakazu Okawa; Yohei Mineharu; Takayuki Kikuchi; Yoshiki Arakawa; Hiroharu Kataoka; Yasushi Takagi; Susumu Miyamoto
Journal:  BMC Neurol       Date:  2021-03-12       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.